Effects of Monacolin K in Nondiabetic Patients with NAFLD: A Pilot Study

Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver condition with significant risk of progression to steatohepatitis and cirrhosis. Therapeutic strategies in NAFLD include lifestyle changes mainly related to dietary interventions and use of drugs or nutritional components that could improve plasma lipid profiles and insulin sensitivity and decrease the local inflammatory response. In this study, we tested the effects of monacolin K, an inhibitor of HMCoA reductase. In a prospective, uncontrolled, open study, we treated 24 patients with NAFLD and mild hypercholesterolemia with 10 mg/day of monacolin K. At baseline and after 26 weeks, we measured in plasma liver tests, lipids, malondialdehyde, and oxidized glutathione, and assessed biochemical steatosis scores, liver elastography, and body composition with bioimpedance analysis. Monacolin K significantly reduced plasma alanine aminotransferase, cholesterol, triglycerides and the homeostatic model assessment (HOMA) index that indicated improved insulin sensitivity. No significant changes were found in body fat mass and visceral fat, nor in liver elastography, while the fatty liver index (FLI) was significantly decreased. Plasma levels of both malondialdehyde and oxidized glutathione were markedly reduced by monacolin K treatment, suggesting a reduction in oxidative stress and lipid peroxidation. In summary, this pilot study suggests possible benefits of monacolin K use in NAFLD patients that could be linked to a reduction in oxidative stress. This hypothesis should be further investigated in future studies.

[1]  C. Catena,et al.  Association of non-alcoholic fatty liver disease with left ventricular changes in treatment-naive patients with uncomplicated hypertension , 2022, Frontiers in Cardiovascular Medicine.

[2]  Yanzhang Li,et al.  Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease , 2022, International journal of molecular sciences.

[3]  Bhornprom Yoysungnoen,et al.  Red Rice Bran Extract Attenuates Adipogenesis and Inflammation on White Adipose Tissues in High-Fat Diet-Induced Obese Mice , 2022, Foods.

[4]  H. El‐Serag,et al.  Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight , 2022, Nature Reviews Gastroenterology & Hepatology.

[5]  C. Catena,et al.  Differences in Regulation of Cortisol Secretion Contribute to Left Ventricular Abnormalities in Patients With Essential Hypertension , 2022, Hypertension.

[6]  C. Catena,et al.  Vitamin D Deficiency Is Associated with Glycometabolic Changes in Nondiabetic Patients with Arterial Hypertension , 2022, Nutrients.

[7]  C. Catena,et al.  Prognostic Role of Malnutrition Diagnosed by Bioelectrical Impedance Vector Analysis in Older Adults Hospitalized with COVID-19 Pneumonia: A Prospective Study , 2021, Nutrients.

[8]  P. Fariselli,et al.  Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. , 2021, Journal of hepatology.

[9]  Pau Vancells Lujan,et al.  Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development , 2021, Nutrients.

[10]  V. Wong,et al.  Non-alcoholic fatty liver disease , 2021, The Lancet.

[11]  Sangam Rajak,et al.  Current treatment paradigms and emerging therapies for NAFLD/NASH. , 2021, Frontiers in bioscience.

[12]  Roberto Rodriguez-Echevarria,et al.  Nutritional Approaches for the Management of Nonalcoholic Fatty Liver Disease: An Evidence-Based Review , 2020, Nutrients.

[13]  C. Valério,et al.  NAFLD as a continuum: from obesity to metabolic syndrome and diabetes , 2020, Diabetology & Metabolic Syndrome.

[14]  Zhiting Chen,et al.  An overview of the bioactivity of monacolin K / lovastatin. , 2019, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[15]  M. Maciejczyk,et al.  Oxidative stress biomarkers in the serum and plasma of patients with non-alcoholic fatty liver disease (NAFLD). Can plasma AGE be a marker of NAFLD? Oxidative stress biomarkers in NAFLD patients , 2019, Free radical research.

[16]  M. Banach,et al.  Red Yeast Rice for Hypercholesterolemia. , 2019, Methodist DeBakey cardiovascular journal.

[17]  M. Moreno-Aliaga,et al.  Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation , 2019, Nutrients.

[18]  M. Friedrich-Rust,et al.  Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. , 2019, Gastroenterology.

[19]  T. Asselah,et al.  Mitochondrial Dysfunction and Signaling in Chronic Liver Diseases. , 2018, Gastroenterology.

[20]  S. Bellentani,et al.  Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence , 2018, Nutrients.

[21]  E. Manzato,et al.  Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper , 2018, Pharmacological research.

[22]  L. Sechi,et al.  Long-Term Renal and Cardiac Outcomes after Stenting in Patients with Resistant Hypertension and Atherosclerotic Renal Artery Stenosis , 2017, Kidney and Blood Pressure Research.

[23]  M. Pergolini,et al.  Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study. , 2017, Atherosclerosis. Supplements.

[24]  A. Facciorusso,et al.  Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis. , 2017, Free radical biology & medicine.

[25]  Lian-hui Chen,et al.  Omega-3 fatty acids as a treatment for non-alcoholic fatty liver disease in children: A systematic review and meta-analysis of randomized controlled trials. , 2016, Clinical nutrition.

[26]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[27]  I. Hatemi,et al.  Role of oxidative stress and insulin resistance in disease severity of non-alcoholic fatty liver disease. , 2016, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[28]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[29]  D. Häussinger,et al.  Evaluation of Acoustic Radiation Force Impulse Imaging (ARFI) for the Determination of Liver Stiffness Using Transient Elastography as a Reference in Children , 2015, Ultrasound International Open.

[30]  F. Violi,et al.  Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. , 2015, World journal of hepatology.

[31]  V. Gerdes,et al.  Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis. , 2015, Atherosclerosis.

[32]  H. Yki-Järvinen.  Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. , 2014, The lancet. Diabetes & endocrinology.

[33]  F. Nascimbeni,et al.  Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease , 2014, Alimentary pharmacology & therapeutics.

[34]  K. Tsuneyama,et al.  Study of the Effects of Monacolin K and Other Constituents of Red Yeast Rice on Obesity, Insulin-Resistance, Hyperlipidemia, and Nonalcoholic Steatohepatitis Using a Mouse Model of Metabolic Syndrome , 2012, Evidence-based complementary and alternative medicine : eCAM.

[35]  L. Sechi,et al.  Oxidative stress is activated by free fatty acids in cultured human hepatocytes. , 2011, Metabolic syndrome and related disorders.

[36]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[37]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[38]  K. Oniki,et al.  Association between combinations of glutathione‐S‐transferase M1, T1 and P1 genotypes and non‐alcoholic fatty liver disease , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[39]  R. Boldrini,et al.  Protein glutathionylation increases in the liver of patients with non‐alcoholic fatty liver disease , 2008, Journal of gastroenterology and hepatology.

[40]  M. Holmqvist,et al.  Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. , 2007, Journal of hepatology.

[41]  C. Catena,et al.  Alcohol-induced endothelial changes are associated with oxidative stress and are rapidly reversed after withdrawal. , 2005, Alcoholism, clinical and experimental research.

[42]  K. Mak,et al.  Model of nonalcoholic steatohepatitis. , 2004, The American journal of clinical nutrition.

[43]  G. Svegliati-Baroni,et al.  Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH , 2019, Transplantation.